Capital Flow Monitor · Sponsors · CIK 2107396
Gilgamesh Pharma Inc.
113 UNIVERSITY PLACE, SUITE 1019, NEW YORK, NY, 10003 · 929-723-4861
Pharmaceuticals · Corporation· inc. DELAWARE true 2025
Fit score
—
Offering
$60.0M
Sold
$60.0M
% sold
100.0%
Investors
40
Min investment
$50K
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2026-03-31 | D | 506(b) | $15.0M | $2.3M | 15.0% | 3 | EDGAR ↗ |
| 2026-03-24 | D ·current | 506(b) | $60.0M | $60.0M | 100.0% | 40 | EDGAR ↗ |
| 2026-02-04 | D | 506(b) | $6.1M | $6.1M | 100.0% | 9 | EDGAR ↗ |
| 2026-02-04 | D | 506(b) | $4.4M | $0 | 0.0% | 8 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- Jonathan Sporn — Executive Officer / Director, New York, NY
- Andrew Kruegel — Executive Officer / Director, New York, NY
- Zia Huque — Director, New York, NY
-
Amy Kruse — Director, New York, NY
2 other raises
- Satori Neuro Partners LP $19.2M of $25.0M · 76.9%
- Satori Neuro Co-Invest LP $3.3M of —
- Robert Berman — Director, New York, NY
- Phil Skolnick — Director, New York, NY
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.